Adverse Event and Quality-of-Life Considerations in Endometrial Cancer

Panelists discuss how managing adverse events and maintaining quality of life are critical when using dostarlimab plus chemotherapy in endometrial cancer. They provide an overview of the regimen’s safety profile, noting common toxicities such as fatigue, gastrointestinal effects, and immune-related events like endocrinopathies or hepatic inflammation. The conversation underscores the importance of proactive monitoring and early intervention to ensure patients can continue therapy safely.

The experts outline practical strategies for managing treatment-related adverse effects, including patient education, multidisciplinary support, and routine lab monitoring. They emphasize that toxicity management should be integrated into the care plan from the outset, as immune-mediated reactions may occur unpredictably or even after therapy completion.

Finally, the panel stresses that individualized assessment—considering patient age, comorbidities, and baseline performance status—is essential to optimizing outcomes. Balancing treatment efficacy with tolerability and quality-of-life goals remains a cornerstone of care, ensuring that advances in immunotherapy translate to meaningful patient benefit.